The Drug-Induced Respiratory Disease Website and App

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.k Flash (fulminate) pulmonary edema

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.k Myocardial stunning

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.v Torsades de pointe

LI. Cardiovascular involvement / toxicity

LI.y Asystole

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

LI. Cardiovascular involvement / toxicity

LI.as Wandering pacemaker

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.k Flash (fulminate) pulmonary edema

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVI. Pulmonary vasculopathy

XLVI.g Foreign body pulmonary vasculopathy (Excipient lung disease)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.i Respiratory arrest - Apnea

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.s Botulism (foodborne-, wound-)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ad Parsonage-Turner amyotrophic neuralgia-like syndrome

L. Miscellaneous

L.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

L. Miscellaneous

L.o Death following exposure or poisoning

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LV. Imaging

LV.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.t Path: Pulmonary edema (see also II/IIa)

LVIII. Pathology

LVIII.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LXV. Veterinary medicine

LXV.e Veterinary: Pulmonary edema

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.h Hypoxemia, low oxygen saturation (may occur in isolation)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.k Flash (fulminate) pulmonary edema

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIII. Airway involvement

XLIII.f Bronchospasm and angioedema

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIII. Airway involvement

XLIII.ac Cough (acute, violent, explosive)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.f Vocal cord dysfunction, adduction, closure, injury

XLVI. Pulmonary vasculopathy

XLVI.e Fat/oil embolism - The FES embolism syndrome

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.i Respiratory arrest - Apnea

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.p Disordered breathing during sleep - Sleep apnea

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.w Multiple organ dysfunction/failure (MODS/MOF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ac Propofol infusion syndrome (PRIS)

L. Miscellaneous

L.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

L. Miscellaneous

L.o Death following exposure or poisoning

L. Miscellaneous

L.u Addictive risk

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.u Cardiac- cardiorespiratory/pulmonary arrest

LI. Cardiovascular involvement / toxicity

LI.y Asystole

LVIII. Pathology

LVIII.be Path: Lipid/fat embolism (see also VIe)

LXV. Veterinary medicine

LXV.l Veterinary: Anaphylaxis/Anaphylactoid reaction

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.j Overload pulmonary edema (including posttransfusional (TACO))

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.k Flash (fulminate) pulmonary edema

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIII. Airway involvement

XLIII.f Bronchospasm and angioedema

XLIII. Airway involvement

XLIII.ac Cough (acute, violent, explosive)

XLVI. Pulmonary vasculopathy

XLVI.e Fat/oil embolism - The FES embolism syndrome

XLVI. Pulmonary vasculopathy

XLVI.z Lipiodol pulmonary embolism

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ar Delayed anaphylaxis

LI. Cardiovascular involvement / toxicity

LI.ai Bradycardia

LVI. Distinctive patterns - 'Eye-catchers'

LVI.h Eye-catcher: Lipiodol embolism

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.k Flash (fulminate) pulmonary edema

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIII. Airway involvement

XLIII.w Bronchiolitis (a clinical-imaging pattern suggestive of)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIII. Airway involvement

XLIII.al Cough variant asthma

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.x Opportunistic large airway infection (bacterial, fungal, viral)

XLVII. Mediastinal involvement

XLVII.g Hemomediastinum - Mediastinal hematoma

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.t CNS involvement/dysfunction/damage

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.b Antiphospholipid antibodies w/wo the APL syndrome

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.aq Flare of preexisting vasculitis

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.w Path: Pulmonary fibrosis (UIP-pattern)

LIX. Infections & related conditions

LIX.a Respiratory tract infection incl. pneumonia

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.m Fungal airway infection

LIX. Infections & related conditions

LIX.q Viral pneumonia

LIX. Infections & related conditions

LIX.v Hypogammaglobulinemia - Antibody deficiency

LXII. Rechallenge data

LXII.c Tolerance can be induced successfully starting with minute dosage of the drug